NRG/RTOG 1005 乳腺癌放疗两步认证中的失败模式与教训
该研究分析 NRG/RTOG 1005 乳腺癌放疗方案中机构认证提交的计划,评估基准测试和快速审查两步 QA 的失败率与原因。结果显示基准测试初始失败率约 17%–18%,同侧肺和心脏剂量约束是最常见失败原因;快速审查轮廓初始失败率 35%,主要源于靶区而非危及器官轮廓。提示多中心乳腺癌放疗试验需严格 QA 以保证质量和一致性。
要点
- 基准测试初始失败率 3DCRT 18%、IMRT 17%、SIB 18%,同侧肺和心脏剂量约束是最常见原因。
- 快速审查轮廓初始失败率 35%,主要源于靶区而非危及器官轮廓。
- 29% 的快速审查初始失败中,PTV boost eval 体积被判定为不可接受偏差。
核心结论
- 同侧肺和心脏剂量约束的可接受变异或不可接受偏差是基准 QA 失败最常见原因。
- 靶区轮廓而非正常结构轮廓的不可接受偏差是快速审查 QA 失败最常见原因。
- 多中心乳腺癌放疗试验需严格 QA 流程以保证高质量和同质性。
研究设计与样本
- NRG/RTOG 1005 允许提交 3DCRT、IMRT 和 SIB 乳腺癌计划。
- 认证要求通过两步 QA:基准测试需无不可接受偏差且 DV 标准中≤1 个可接受变异;快速审查需首次方案提交 DV 标准或轮廓无不可接受偏差。
- 352 家机构参与基准 QA,280 例入组患者接受快速审查 QA。
主要发现
- 基准初始失败率 3DCRT 18%、IMRT 17%、SIB 18%。
- 3DCRT 和 IMRT 基准计划中同侧肺最常未通过 DV 标准,SIB 中 Gunn 心脏最常未通过。
- 快速审查轮廓初始失败率 35%,归因于靶区而非危及器官。
- 29% 的快速审查初始失败中 PTV boost eval 体积被判定为不可接受偏差。
临床怎么用
- 乳腺癌多中心放疗试验中应重点关注同侧肺和心脏剂量约束的 QA。
- 靶区轮廓质量是快速审查 QA 的关键环节,需加强靶区勾画培训与审核。
- 严格的两步 QA 流程有助于确保放疗获益大于风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate patterns of failure in institutional credentialing submissions to NRG/RTOG 1005 with the aim of improving the quality and consistency for future breast cancer protocols. METHODS AND MATERIALS: NRG/RTOG 1005 allowed the submission of 3-dimensional conformal radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), and simultaneous integrated boost (SIB) breast plans. Credentialing required institutions to pass a 2-step quality assurance (QA) process: (1) benchmark, requiring institutions to create a plan with no unacceptable deviations and ≤1 acceptable variation among the dose volume (DV) criteria, and (2) rapid review, requiring each institution's first protocol submission to have no unacceptable deviations among the DV criteria or contours. Overall rates, number of resubmissions, and reasons for resubmission were analyzed for each QA step. RESULTS: In total, 352 institutions participated in benchmark QA and 280 patients enrolled had rapid review QA. Benchmark initial failure rates were similar for 3DCRT (18%), IMRT (17%), and SIB (18%) plans. For 3DCRT and IMRT benchmark plans, ipsilateral lung most frequently failed the DV criteria, and SIB DV failures were seen most frequently for the heart. Rapid review contour initial failures (35%) were due to target rather than organs at risk. For 29% of the rapid review initial failures, the planning target volume boost eval volume was deemed an unacceptable deviation. CONCLUSIONS: The review of the benchmark and rapid review QA submissions indicates that acceptable variations or unacceptable deviations for the ipsilateral lung and heart dose constraints were the most commonly observed cause of benchmark QA failure, and unacceptable deviations in target contouring, rather than normal structure contouring, were the most common cause of rapid review QA failure. These findings suggest that a rigorous QA process is necessary for high quality and homogeneity in radiation therapy in multi-institutional trials of breast cancer to ensure that the benefits of radiation therapy far outweigh the risks.
引用
- Li XA, Moughan J, White JR, et al. Patterns of Failure Observed in the 2-Step Institution Credentialing Process for NRG Oncology/Radiation Therapy Oncology Group 1005 (NCT01349322) and Lessons Learned. Pract Radiat Oncol. 2019. PMID: 31790823. doi:10.1016/j.prro.2019.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。